C. Grace Yeh is Founder, Chairman and CEO of Onward Therapeutics SA, a Swiss biopharmaceutical company, which signed a license and co-development agreement, as well as made equity investment in BIOMUNEX in February 2021. Prior to Onward, she was Founder, President and Chief Executive Officer of PharmaEngine, Inc., a publicly traded commercial stage oncology company that developed Onivyde for metastatic pancreatic cancer, which has been approved in more than 40 countries. Grace also served in senior positions at Millennium Pharmaceuticals, LeukoSite, CytoMed, and T Cell Sciences, all based in Cambridge, MA, USA. Before joining the industry, she worked in academic research at INSERM in France and Blond Mclndoe Centre for Transplantation Biology in England. Grace has a PhD in Immunology from Medical University of South Carolina, USA. She received the 2016 EY Entrepreneur Award of the Year and the Industrial Technology Research Institute (ITRI) Laureate for her lifetime achievement in biotechnology in 2021.